A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV

We administered a questionnaire to participants who received different vaccination regimens to evaluate the effectiveness of Ad5-vectored COVID-19 vaccines. The results showed that administration of intramuscular Ad5-nCoV provided 21.32% more protection against SARS-CoV-2 infection than that of the inactivated COVID-19 vaccine in people who had received only one type of COVID-19 vaccine. Furthermore, aerosolized Ad5-nCoV exhibited good protection, whether it was administered as a homologous booster to people vaccinated with the intramuscular Ad5-nCoV or as a heterologous booster to people vaccinated with inactivated COVID-19 vaccines. Our research indicates that Ad5-nCoV is an effective booster. This finding supports the future selection of COVID-19 immunization strategies.

本研究针对接种不同免疫程序的受试者开展问卷调查，以评估腺病毒载体5型新冠疫苗（Ad5-vectored COVID-19 vaccines）的防护有效性。结果显示，在仅接种过单一类型新冠疫苗的人群中，肌内注射型Ad5-nCoV疫苗对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染的防护效力较新冠灭活疫苗高出21.32%。此外，雾化吸入型Ad5-nCoV疫苗展现出优异的防护效果，无论其作为同源加强针应用于已接种肌内注射型Ad5-nCoV疫苗的受试者，还是作为异源加强针应用于已接种新冠灭活疫苗的人群。本研究证实Ad5-nCoV是一款高效的新冠疫苗加强针，该发现可为未来新冠免疫接种策略的选择提供有力支撑。